Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Pump's daily trading recs, emphasis on short selling -- Ignore unavailable to you. Want to Upgrade?

To: Mud who wrote (5396)	8/24/2001 2:39:04 PM
From: rellabourn	Read Replies (2) \| Respond to of 6873

Mud, Thanks for VPHM... some quick DD shows a book value of .01 with Debt/Equity ratio of 1,735...Do you know if this correct? I've never seen a company with that much debt. I bought Oct 35 puts at 4.20. Rella

To: Mud who wrote (5396)	8/24/2001 8:51:12 PM
From: Mark L.	Read Replies (3) \| Respond to of 6873

VPHM Shorted this one before and made money off of the common cold, as did they....IT is in the short area again with the same old news... Different news, different management, different balance sheet, different financiers, and no sleazy promoters this time. I shorted it twice in 2000. I'm long now. Pleconaril is not going to CURE the common cold and will probably be marketed only to people with weakened immune systems. Effectiveness is only in the 1 1/2 day range. It's an important step, and maybe they'll be able to refine its effectiveness in the future. Given the size of the market, Pleconaril's potential, and today's run-up, it doesn't appear to me particularly mis-priced, either high or low. If you are shorting it out of reflex, I would urge you to do a little more research.